Startup DNA Script, incubated at Agoranov in 2015, extends its Series C by €30M to reach a total amount of €172M

‍

This Tuesday, January 4, 2022, the startup announced an extension of its Series C by €30 million to reach a total amount of €172 million. This will allow it to accelerate its deployment on all continents of the world.

‍

DNA Script gives any medical structure the ability to print DNA using an enzymatic technology.

‍

"DNA is used to program biological organisms. We wanted to provide a solution that would allow researchers to control the system," explains Thomas Ybert, president and co-founder of DNA Script.

‍

This transaction sees seven American investment funds join DNA Script: Coatue Management and Catalio Capital Management, followed by Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Moore Strategic Ventures and Farallon Capital.
Thanks to this extension, four new funds are also joining the startup's capital: Baillie Gifford, Healthcore Management, EureKare and Irving Investors.

This gives DNA Script a financial visibility of more than 3 years. It brings the total amount raised by the company to €266.5 million, including €81 million for the Series B round closed in two stages (2019 and 2020) , €11 million for the Series A round in 2017 and €2.5 million for the seed round led in 2016 by Sofinnova Partners.

Some historical investors such as Casdin Capital, LSP, Illumina Ventures, Bpifrance via its Large Venture fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners and Alexandria Venture Investments also participated in this financing.

‍

"These are long-term partners with an excellent track record of previous investments," says Thomas Ybert.

‍

Congratulations to the team and good luck!

‍